Abstract: A display device including: a first elastic member, a display portion disposed on the first elastic member; and a sensing material layer disposed between the first elastic member and the display portion, wherein the display portion including a first island pattern, a second island pattern, and a slit, wherein the first island pattern and the second island pattern are spaced apart from each other with the slit therebetween, and each of the first island pattern and the second island pattern includes a pixel, and wherein the sensing material layer overlaps the slit.

Abstract: The present disclosure relates to a DC-DC converter, a vehicle, and a control method including the same, and more particularly, to a DC-DC converter, a vehicle, and a control method including the same capable of effectively detecting and responding to an interlock failure of a connector.

Abstract: The present invention relates to novel C-glycosyltransferase variants and a use thereof. The C-glycosyltransferase variants according to the present invention have improved glycosidic bond-forming ability as compared with wild-type C-glycosyltransferase, and thus can increase the glycoside production effects of polyketide groups and pseudo-natural products, particularly type I, II, III polyketide, nonribosomal peptides, phenylpropanoids, and other aromatic natural products, and thus can be useful for the preparation of a drug, a food additive, a nutritional supplement, and the like containing a C-glycoside compound as a constituent ingredient.

Abstract: A coil component includes a body; first and second coil portions spaced apart from each other in the body; first and second external electrodes disposed on the body to be spaced apart from each other and connected to both ends of the first coil portion; and first and second ground electrodes spaced apart from each other on the body and connected to both ends of the second coil portion.

Abstract: A cylinder unit detachably coupled to a housing unit including a cutting unit detachably coupled to the cylinder unit, the cutting unit configured to move, responsive to an operation of the cylinder unit, toward an injection molding unit to cut a gate of an injection-molded object, a cover core unit detachably coupled to the injection molding unit, the cover core unit configured to face the gate, wherein the cutting unit passes through the cover core unit, and a cutting core unit detachably coupled to the cover core unit, the cutting core unit configured to face the gate, wherein the cutting unit passes through the cutting core unit.

Abstract: The present invention relates to a crystalline form I represented by formula 1, a method for preparing the same, and a pharmaceutical composition comprising the same. The crystalline form I represented by formula 1 of the present invention may be characterized by XRPD patterns, DSC profiles, TGA profiles, and/or DVS profiles.

Abstract: The present invention relates to a crystalline form IV represented by formula 1, a method for preparing the same, and a pharmaceutical composition comprising the same. The crystalline form IV represented by formula 1 of the present invention may be characterized by XRD patterns, DSC profiles, and/or TGA profiles.

Abstract: The present invention relates to a crystalline form II represented by formula 1, a method for preparing the same, and a pharmaceutical composition comprising the same. The crystalline form II represented by formula 1 of the present invention may be characterized by XRD patterns, DSC profiles, and/or TGA profiles.

Abstract: The present invention relates to a crystalline form III represented by formula 1, a method for preparing the same, and a pharmaceutical composition comprising the same. The crystalline form III represented by formula 1 of the present invention may be characterized by XRD patterns, DSC profiles, and/or TGA profiles.

Abstract: The present invention relates to a crystalline form I represented by formula 1, a method for preparing the same, and a pharmaceutical composition comprising the same. The crystalline form I represented by formula 1 of the present invention may be characterized by XRD patterns, DSC profiles, and/or TGA profiles.

Abstract: The present invention relates to a biaryl derivative expressed by the chemical formula 1, a method for producing the biaryl derivative, a pharmaceutical composition comprising same, and use of same, the biaryl derivative expressed by the chemical formula 1, as a GPR120 agonist, promoting GLP-1 generation in the gastro-intestinal tract, reducing insulin resistance in the liver, muscles and the like from anti-inflammatory activity in the macrophage, pancreatic cells and the like, and allowing effective use in prevention or treatment of inflammation or metabolic diseases such as diabetes, complications from diabetes, obesity, non-alcoholic fatty liver disease, fatty liver disease, and osteoporosis.

Abstract: Compounds having the chemical formula 1, a method for producing the compounds of chemical formula 1, a pharmaceutical composition comprising same, and use thereof as a GPR120 agonist for prevention or treatment of inflammation or metabolic diseases such as diabetes, complications from diabetes, obesity, non-alcoholic fatty liver disease, fatty liver disease, and osteoporosis.

Abstract: A thinner composition is capable of reducing the amount of photoresist used in a reducing resist consumption (RRC) coating process, an edge bead removed (EBR) process or the like, and removing unnecessary photoresist on an edge portion or a backside portion of the wafer. The thinner composition includes C1-C10 alkyl C1-C10 alkoxy propionate, propylene glycol C1-C10 alkyl ether, and propylene glycol C1-C10 alkyl ether acetate.

Abstract: A moxibustion apparatus includes: a case; a heat storage unit arranged inside the case and including a heat storage material, a heat insulating member covering an outer surface of the heat storage material, an exposed portion exposed to the outside of the heat insulating member, a heating coil embedded in the heat storage material and electrically heated, and a charging terminal that has one side exposed to the outside of the case and is connected to an external power source to provide power to the heating coil; and a moxibustion unit configured to receive heat accumulated in the heat storage material through the exposed portion to locally heat acupuncture points of a user's abdomen, and including a protrusion portion that protrudes to have an end portion thereof formed into a spherical shape or a gently curved shape and is exposed to the outside of the case.

Abstract: A thinner composition is capable of reducing the amount of photoresist used in a reducing resist consumption (RRC) coating process, an edge bead removed (EBR) process or the like, and removing unnecessary photoresist on an edge portion or a backside portion of the wafer. The thinner composition includes C1-C10 alkyl C1-C10 alkoxy propionate, propylene glycol C1-C10 alkyl ether, and propylene glycol C1-C10 alkyl ether acetate.

Abstract: A moxibustion apparatus includes: a case; a heat storage unit arranged inside the case and including a heat storage material, a heat insulating member covering an outer surface of the heat storage material, an exposed portion exposed to the outside of the heat insulating member, a heating coil embedded in the heat storage material and electrically heated, and a charging terminal that has one side exposed to the outside of the case and is connected to an external power source to provide power to the heating coil; and a moxibustion unit configured to receive heat accumulated in the heat storage material through the exposed portion to locally heat acupuncture points of a user's abdomen, and including a protrusion portion that protrudes to have an end portion thereof formed into a spherical shape or a gently curved shape and is exposed to the outside of the case.

Abstract: The present invention relates to a biaryl derivative expressed by the chemical formula 1, a method for producing the biaryl derivative, a pharmaceutical composition comprising same, and use of same, the biaryl derivative expressed by the chemical formula 1, as a GPR120 agonist, promoting GLP-1 generation in the gastro-intestinal tract, reducing insulin resistance in the liver, muscles and the like from anti-inflammatory activity in the macrophage, pancreatic cells and the like, and allowing effective use in prevention or treatment of inflammation or metabolic diseases such as diabetes, complications from diabetes, obesity, non-alcoholic fatty liver disease, fatty liver disease, and osteoporosis.

Abstract: The present invention relates to thioaryl derivatives of Formula 1 as defined in the specification, a method for preparing the same, a pharmaceutical composition comprising the same and use thereof. The thioaryl derivatives of Formula 1 according to the present invention promote GLP-1 formation in the gastrointestinal tract and improve insulin resistance in macrophages, pancreas cells, etc. due to anti-inflammatory action, and can accordingly be effectively used for preventing or treating diabetes, complications of diabetes, inflammation, obesity, non-alcoholic fatty liver, steatohepatitis or osteoporosis.

Abstract: A backlight assembly is disclosed that is capable of enabling easy narrow bezel design and easily radiating heat generated from a light source, and a liquid crystal display device using the same. The backlight assembly includes a bottom cover, a light guide plate placed on the bottom cover, a printed circuit board having an L-shaped form and attached to a bottom surface and inner lateral surface of the bottom cover, and a plurality of Light Emitting Diode (LED) packages being mounted to the printed circuit board, wherein the printed circuit board includes a single metal layer having the L-shaped form and attached to the bottom surface and the inner lateral surface of the bottom cover; and a Resin Coated Copper (RCC) film attached to an inner lateral surface of the single metal layer.

Abstract: The present invention relates to thioaryl derivatives of Formula 1 as defined in the specification, a method for preparing the same, a pharmaceutical composition comprising the same and use thereof. The thioaryl derivatives of Formula 1 according to the present invention promote GLP-1 formation in the gastrointestinal tract and improve insulin resistance in macrophages, pancreas cells, etc. due to anti-inflammatory action, and can accordingly be effectively used for preventing or treating diabetes, complications of diabetes, inflammation, obesity, non-alcoholic fatty liver, steatohepatitis or osteoporosis.